GID BIO IN THE NEWS

Read how recent cell-based therapy discoveries are impacting the field of medicine.

Cell Therapy News

Late-stage biotech GID BIO wins funding from Richard King Mellon Foundation to study cellular therapy as a potential therapeutic for severe respiratory distress

Study to treat hospitalized COVID-19 patients applies same technology platform and point-of-care cellular therapy used in a pivotal/Phase III trial for osteoarthritis LOUISVILLE, Colo. and PITTSBURGH, Aug. 18, 2020 /PRNewswire/ — Following FDA clearance of an expanded access protocol to treat a small group of COVID-19 patients using the GID BIO technology platform,

Learn More »

GID BIO seeks up to USD 25m to support cellular therapy platform, CEO says

Mergermarket is the leading provider of forward-looking M&A intelligence and data to investment banks, private equity firms, law firms, accounting firms, corporates and other M&A professionals around the world. WWW.MERGERMARKET.COM JANUARY 16, 2020 BY DEB BALSHEM GID BIO, a privately held cellular therapy company, is looking to raise between USD

Learn More »

6 Orthobiologic Companies Move Clinical Trials Forward

Multiple orthobiologic companies have engaged in clinical trials in 2019, seeking to demonstrate the efficacy of their cell-based products…. GID BIO completed a multi-site, randomized, placebo-controlled Phase IIb clinical trial with an FDA-approved study design using autologous stromal cells in the treatment of knee osteoarthritis (OA), successfully meeting endpoints and two-year safety results…

Learn More »
✉ RECEIVE OUR NEWSLETTER   
Scroll to Top